CAMBRIDGE, Mass., and BEIJING, China, May 04, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. BGNE, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston. The presentation is scheduled for 9:20 AM ET on Tuesday, May 8, 2018.
A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
Investor Contact
Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
Media Contact
Liza Heapes
+ 1 857-302-5663
media@beigene.com
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.